Close Navigation
About ArixStrategy
OverviewInvestment CaseNewsResultsDocumentsEventsCalendarAnalystsStock infoContact
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

News & Media

Read our latest news, and find more about us and our portfolio companies.

Read the latest Arix Bioscience newsletter
NewsMedia

22nd May 2023

Pharmaceutical Technology

Readmission on the Horizon: How EU funding can boost British biotech

27th April 2023

Pharmaceutical Technology

Evommune gains funding to accelerate therapies for chronic inflammatory diseases

26th April 2023

Investors' Chronicle

A biotech stock at an unwarranted discount

26th April 2023

Endpoints

Evommune raises $50M to fund clinical trials in skin diseases

25th April 2023

Shares Magazine

Arix Bioscience narrows annual loss but net asset value decreases

21st February 2023

Labiotech

Disc Medicine raises $62.5M for hematology programs

21st February 2023

End Points

With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital

9th February 2023

Investors' Chronicle

Bargain Shares 2023

27th January 2023

Technology Networks

New Approaches for Cancer Therapies: Targeting the DNA Damage Response

9th January 2023

The Pharma Letter

Ensoma Announces Financing and Acquisition

6th January 2023

Labiotech

Ensoma Acquiring Twelve Bio

6th January 2023

EndPoints

On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M

16th October 2022

MedCity News

Cancer drug biotech Enliven shifts to reverse to move forward as a public company

14th October 2022

BioCentury

Oct. 14 Quick Takes

3rd October 2022

Endpoints

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

17th August 2022

Business Weekly

Artios Pharma trials new breast cancer treatment

12th August 2022

Shares Magazine

Arix Bioscience NAV falls; portfolio firm Disc to merge with Gemini

12th August 2022

Investors' Chronicle

A Ben Graham recovery play

10th August 2022

Endpoints

Disc Medicine goes public in reverse merger with struggling Gemini Therapeutics

10th August 2022

Fierce Biotech

Disc inks Gemini merger, secures cash from starry VC syndicate to advance ex-AbbVie, Roche drugs

27th July 2022

The Economist

The life-sciences industry is a jewel in Britain’s economy

13th June 2022

Business Weekly

The Killer 50 Profiles

10th May 2022

Investors' Chronicle

Bargain Shares: A Ben Graham contrarian value play

21st April 2022

Utah Business

Sorriso Pharmaceuticals is creating the first orally-delivered anti-inflammatory drug for patients with IBD

1st April 2022

The Herald Scotland

New ovarian cancer study to probe causes of PARP inhibitor resistance

3rd March 2022

Targeted Oncology

FDA Grants Fast Track Designation to HPN217 for R/R Multiple Myeloma

22nd December 2021

Finsmes

Sorriso Pharmaceuticals Raises $31M in Series A Funding

22nd December 2021

Citybiz

NEA Co-Leads $31 Million Series A in Sorriso Pharmaceuticals

22nd December 2021

Endpoints

Biotech vets jump on board a startup, raise cash and take aim at the clinic with anti-inflammatory drugs

16th December 2021

Health Investor

Depixus raises €30.6m in Series A financing

15th December 2021

European Biotechnology

Depixus raises €30.6m in Series A financing

15th December 2021

Genome Web

Nucleic Acid Analysis Startup Depixus Raises €30.6M in Series A Financing

9th November 2021

Investors' Chronicle

Bargain shares: On the M&A beat

2nd November 2021

End Points

Intracellular targets, eye cancer therapy and light-activated skincare: Here's the latest on biotech IPOs

11th October 2021

Investors Chronicle

Bargain shares: A heavily oversold biotech value recovery play

6th September 2021

PharmaLive

Investors Hand Disc Medicine $90 Million To Control Hematological Diseases

6th September 2021

Endpoints

Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

6th September 2021

Fierce Biotech

Disc Medicine nabs $90M for blood disease pipeline, new Roche asset

29th July 2021

BioWorld

Artios’ $153M series C to expand DDR platform beyond synthetic lethality

29th July 2021

Endpoints

Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors

29th July 2021

Fierce Biotech

Artios raises $153M to fund DNA damage repair clinical trials

17th May 2021

In Vivo

In Vivo's 2021 Rising Leaders: Recognizing Talent Across The Life Sciences

10th May 2021

The Times

Inside Track: Amplyx's Ciara Kennedy is on the boil after fungi-fighting Pfizer buyout

6th May 2021

EndPoints

Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout

6th May 2021

Fierce Biotech

Pfizer buys Amplyx to grow infectious disease pipeline

9th April 2021

Pharma Times

Artios, Novartis form cancer therapies collaboration

9th April 2021

Fierce Biotech

Novartis taps Artios for targets to enhance radioligand drugs

9th April 2021

Investors Chronicle

Five Investment Company Bargains

30th March 2021

The Business Journals

Oncology startup to double size with $152M

10th March 2021

INVESTORS CHRONICLE

Clean up with two deep value plays

10th March 2021

Scrip

New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech

9th March 2021

Vox Markets

Arix Bioscience reports FY20NAV up 62%

9th March 2021

PROACTIVE

Arix Bioscience sees sharp uplift in net asset value in 2020

9th March 2021

ASKTRADERS

Arix Bioscience Shares Rally 5.4% as Net Asset Value Surges on VelosBio Sale to Merck

9th March 2021

EVENING STANDARD

Arix Bioscience sees value rocket 62% as UK biotech scene booms

1st March 2021

C&EN

The Fight Against Fungi

5th February 2021

Investors Chronicle

Bargain shares for 2021

3rd February 2021

LSX Leaders

LSX London 2021 Biotech - Accelerating Innovation Through Early-Stage Investment

26th January 2021

Pharmaphorum

Biden administration – What can the healthcare industry expect?

21st January 2021

OneNucleus

Around the World in Venture Capital

6th January 2021

Citywire

David Stevenson: This is my portfolio for 2021

11th December 2020

Investors chronicle

Exploit Arix Bioscience’s huge margin of safety

11th December 2020

PROACTIVE

Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment

10th December 2020

Financial Times

Why Tech trend is worth following beyond 2020

3rd December 2020

Shares Magazine

Arix Bioscience shares rise on collaboration deal with Merck KGaA

3rd December 2020

Proactive

Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn

12th November 2020

Shares Magazine

Latest takeovers focus on two specific groups of stocks

23rd September 2020

In Vivo

Deal-Making During A Pandemic And 2021 Expectations

Arix Bioscience

About Arix

The Team

Portfolio

Insights

News & Events

Contact

Investor Relations

Results Centre

Financial Calendar

Regulatory News

Document Library

Analysts & Advisors

Shareholder Information

Meta

Privacy Policy

Terms of use

Cookie Policy

Stay up to date

Sign up to receive regulatory news and results

Subscribe
Arix Bioscience
linkedintwitter

Arix Bioscience plc, registered in England and Wales with company number 09777975

Registered office: Duke Street House, 50 Duke Street, London, W1K 6JL, United Kingdom

Website by Ether